Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN)

Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?

Dirk Rades, Daniel Seidl, Stefan Janssen, Amira Bajrovic, Samer G. Hakim, Barbara Wollenberg, Katarina Karner, Primoz Strojan, Steven E. Schild

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

SummaryObjectives To compare chemoradiation with 100 mg/m2 cisplatin every three weeks to 20 mg/m2 on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). Materials and methods In 230 patients receiving chemoradiation for LASCCHN, 100 mg/m2 cisplatin every three weeks (N = 126) and 20 mg/m2 cisplatin on five days every four weeks (N = 104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. Results On univariate analyses, chemoradiation had no impact on LRC (p = 0.53), MFS (p = 0.67) and OS (p = 0.14). On multivariate analysis of LRC, T-classification (p = 0.045) and hemoglobin (p <0.001) were significant. On multivariate analysis of MFS, performance score (p = 0.028) was significant. On multivariate analysis of OS, performance score (p = 0.009) and hemoglobin levels (p = 0.002) achieved significance. Chemoradiation with 100 mg/m2 cisplatin was associated with more pneumonia/sepsis (p = 0.003), grade ≥2 nausea/vomiting (p <0.001), grade ≥2 nephrotoxicity (p = 0.005), grade ≥2 xerostomia (p = 0.002), grade ≥3 hematotoxicity (p = 0.052) and grade ≥2 ototoxicity (p = 0.048). Concluding statement 20 mg/m2 cisplatin on five days every four weeks was associated with fewer adverse events than 100 mg/m2 cisplatin every three weeks. 100 mg/m2 cisplatin was not significantly superior to 20 mg/m2 cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20 mg/m2 cisplatin appeared preferable. The results should be confirmed in a randomized trial.

Original languageEnglish (US)
Pages (from-to)67-72
Number of pages6
JournalOral Oncology
Volume59
DOIs
StatePublished - Aug 1 2016

Fingerprint

Cisplatin
Survival
Neoplasm Metastasis
Hemoglobins
Multivariate Analysis
Carcinoma, squamous cell of head and neck
Xerostomia
Neoplasm Grading
Nausea
Vomiting
Sepsis
Pneumonia
Retrospective Studies
Radiation

Keywords

  • Adverse events
  • Chemoradiation
  • Higher-dose cisplatin
  • LASCCHN
  • Lower-dose fractionated cisplatin
  • Treatment outcomes

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN) : Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks? / Rades, Dirk; Seidl, Daniel; Janssen, Stefan; Bajrovic, Amira; Hakim, Samer G.; Wollenberg, Barbara; Karner, Katarina; Strojan, Primoz; Schild, Steven E.

In: Oral Oncology, Vol. 59, 01.08.2016, p. 67-72.

Research output: Contribution to journalArticle

Rades, Dirk ; Seidl, Daniel ; Janssen, Stefan ; Bajrovic, Amira ; Hakim, Samer G. ; Wollenberg, Barbara ; Karner, Katarina ; Strojan, Primoz ; Schild, Steven E. / Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN) : Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?. In: Oral Oncology. 2016 ; Vol. 59. pp. 67-72.
@article{683ac0bdc95a4a9fa01c5050df7b625e,
title = "Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?",
abstract = "SummaryObjectives To compare chemoradiation with 100 mg/m2 cisplatin every three weeks to 20 mg/m2 on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). Materials and methods In 230 patients receiving chemoradiation for LASCCHN, 100 mg/m2 cisplatin every three weeks (N = 126) and 20 mg/m2 cisplatin on five days every four weeks (N = 104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. Results On univariate analyses, chemoradiation had no impact on LRC (p = 0.53), MFS (p = 0.67) and OS (p = 0.14). On multivariate analysis of LRC, T-classification (p = 0.045) and hemoglobin (p <0.001) were significant. On multivariate analysis of MFS, performance score (p = 0.028) was significant. On multivariate analysis of OS, performance score (p = 0.009) and hemoglobin levels (p = 0.002) achieved significance. Chemoradiation with 100 mg/m2 cisplatin was associated with more pneumonia/sepsis (p = 0.003), grade ≥2 nausea/vomiting (p <0.001), grade ≥2 nephrotoxicity (p = 0.005), grade ≥2 xerostomia (p = 0.002), grade ≥3 hematotoxicity (p = 0.052) and grade ≥2 ototoxicity (p = 0.048). Concluding statement 20 mg/m2 cisplatin on five days every four weeks was associated with fewer adverse events than 100 mg/m2 cisplatin every three weeks. 100 mg/m2 cisplatin was not significantly superior to 20 mg/m2 cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20 mg/m2 cisplatin appeared preferable. The results should be confirmed in a randomized trial.",
keywords = "Adverse events, Chemoradiation, Higher-dose cisplatin, LASCCHN, Lower-dose fractionated cisplatin, Treatment outcomes",
author = "Dirk Rades and Daniel Seidl and Stefan Janssen and Amira Bajrovic and Hakim, {Samer G.} and Barbara Wollenberg and Katarina Karner and Primoz Strojan and Schild, {Steven E.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.oraloncology.2016.06.004",
language = "English (US)",
volume = "59",
pages = "67--72",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN)

T2 - Is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?

AU - Rades, Dirk

AU - Seidl, Daniel

AU - Janssen, Stefan

AU - Bajrovic, Amira

AU - Hakim, Samer G.

AU - Wollenberg, Barbara

AU - Karner, Katarina

AU - Strojan, Primoz

AU - Schild, Steven E.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - SummaryObjectives To compare chemoradiation with 100 mg/m2 cisplatin every three weeks to 20 mg/m2 on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). Materials and methods In 230 patients receiving chemoradiation for LASCCHN, 100 mg/m2 cisplatin every three weeks (N = 126) and 20 mg/m2 cisplatin on five days every four weeks (N = 104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. Results On univariate analyses, chemoradiation had no impact on LRC (p = 0.53), MFS (p = 0.67) and OS (p = 0.14). On multivariate analysis of LRC, T-classification (p = 0.045) and hemoglobin (p <0.001) were significant. On multivariate analysis of MFS, performance score (p = 0.028) was significant. On multivariate analysis of OS, performance score (p = 0.009) and hemoglobin levels (p = 0.002) achieved significance. Chemoradiation with 100 mg/m2 cisplatin was associated with more pneumonia/sepsis (p = 0.003), grade ≥2 nausea/vomiting (p <0.001), grade ≥2 nephrotoxicity (p = 0.005), grade ≥2 xerostomia (p = 0.002), grade ≥3 hematotoxicity (p = 0.052) and grade ≥2 ototoxicity (p = 0.048). Concluding statement 20 mg/m2 cisplatin on five days every four weeks was associated with fewer adverse events than 100 mg/m2 cisplatin every three weeks. 100 mg/m2 cisplatin was not significantly superior to 20 mg/m2 cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20 mg/m2 cisplatin appeared preferable. The results should be confirmed in a randomized trial.

AB - SummaryObjectives To compare chemoradiation with 100 mg/m2 cisplatin every three weeks to 20 mg/m2 on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). Materials and methods In 230 patients receiving chemoradiation for LASCCHN, 100 mg/m2 cisplatin every three weeks (N = 126) and 20 mg/m2 cisplatin on five days every four weeks (N = 104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. Results On univariate analyses, chemoradiation had no impact on LRC (p = 0.53), MFS (p = 0.67) and OS (p = 0.14). On multivariate analysis of LRC, T-classification (p = 0.045) and hemoglobin (p <0.001) were significant. On multivariate analysis of MFS, performance score (p = 0.028) was significant. On multivariate analysis of OS, performance score (p = 0.009) and hemoglobin levels (p = 0.002) achieved significance. Chemoradiation with 100 mg/m2 cisplatin was associated with more pneumonia/sepsis (p = 0.003), grade ≥2 nausea/vomiting (p <0.001), grade ≥2 nephrotoxicity (p = 0.005), grade ≥2 xerostomia (p = 0.002), grade ≥3 hematotoxicity (p = 0.052) and grade ≥2 ototoxicity (p = 0.048). Concluding statement 20 mg/m2 cisplatin on five days every four weeks was associated with fewer adverse events than 100 mg/m2 cisplatin every three weeks. 100 mg/m2 cisplatin was not significantly superior to 20 mg/m2 cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20 mg/m2 cisplatin appeared preferable. The results should be confirmed in a randomized trial.

KW - Adverse events

KW - Chemoradiation

KW - Higher-dose cisplatin

KW - LASCCHN

KW - Lower-dose fractionated cisplatin

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=84975166579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975166579&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2016.06.004

DO - 10.1016/j.oraloncology.2016.06.004

M3 - Article

VL - 59

SP - 67

EP - 72

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -